Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
- Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year
- Unprecedented 100% BMT access and engraftment in evaluable patients receiving a therapeutic dose of Iomab-B despite high leukemia burden and multiple lines of prior treatment
- Iomab-B has also demonstrated improved outcomes in patients with high-risk features including a TP53 mutation
Dr.
Response Rates in Patients Age 65 and Above by
|
Iomab-B (N=28) |
Crossover (N=17) |
Control Arm (N=9) |
Achieved CR or CRp |
19 (67.9 %) |
9 (52.9 %) |
3 (33.3 %) |
Achieved durable CR |
5 (17.9 %) |
1 (5.9 %) |
0 (0.0 %) |
Overall Survival in Patients Age 65 and Above by Treatment Received
|
Iomab-B & Crossover (N=45) |
Control Arm (N=9) |
1-year survival |
20.1 % |
0.0 % |
2-year survival |
11.5 % |
0.0 % |
About the TCT Tandem Meetings
The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the
About
Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA (EU)), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 220 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the
Investors:
investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-announces-iomab-b-markedly-increases-long-term-survival-in-patients-65-years-or-older-with-active-relapsed-or-refractory-aml-in-the-phase-3-sierra-trial-at-the-2024-tandem-meetings--transplantation--cellular-therapy-mee-302070665.html
SOURCE